STAT1h
Pharmalittle: We’re reading about FDA morale, pharma removing DEI goals, and more
Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...
FierceBiotech4h
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...
Investor's Business Daily on MSN2h
Moderna Adds Onto Its 94% Dive With Light Fourth-Quarter Profit
Covid vaccine maker Moderna posted a mixed fourth-quarter report Friday and Moderna stock skidded in early action.
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...
FiercePharma20h
Moderna trims digital team, lays off employees as chief information officer departs
Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, ...
Fact Check: Moderna began clinical trials of COVID vaccine in 2020, not 2017
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
No, Moderna Did Not Create Its COVID Vaccine Two Years Before the Pandemic
An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...
MassLive.com on MSN11d
Mass.-based Moderna could be first to manufacture bird flu vaccine
A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...
Could Moderna’s (MRNA) 65% Stock Plunge Entice a Takeover?
Moderna (MRNA), once a pandemic-era darling, has seen its stock plummet 65% over the past year, battered by fading vaccine ...
Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna Inc.’s stock fell 3% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting a revenue beat. Cambridge, Mass.-based ...